logo

CLRB

Cellectar·NASDAQ
--
--(--)
--
--(--)

CLRB fundamentals

Cellectar (CLRB) released its earnings on Mar 4, 2026: revenue was 0 (YoY --), met estimates; EPS was 0.65 (YoY +130.95%), beat estimates.
Revenue / YoY
0
--
EPS / YoY
0.65
+130.95%
Report date
Mar 4, 2026
CLRB Earnings Call Summary for Q4,2025
  • Iopofosine Regulatory Advance: Conditional EU application submission Q3 2026; U.S. Accelerated Approval pathway with confirmatory Phase III trial.
  • Pipeline Expansion: CLR 125 Phase 1b underway; CLR 225 IND-ready with isotope supply secured.
  • Financial Resilience: $15.2M raised in 2025 extends cash runway to Q3 2026.
  • Clinical Momentum: 12-month data shows improved durability in earlier-line WM patients; global IP portfolio expanded.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

Cellectar (CLRB) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Cellectar (CLRB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

Cellectar (CLRB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

Cellectar (CLRB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does Cellectar (CLRB) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track Cellectar (CLRB) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield